GSK withdraws sNDA for prostate cancer drug Avodart
Published at: www.pharmabiz.com
-
GSK withdraws sNDA for Avodart as prostate cancer chemopreventative drug
March 10, 2010
Dutastaride (Avodart) has been used for treatment of symptomatic benign prostatic hypertrophy. It has been shown effective in reducing prostate volume, symptoms related to prostatic enlargement and PSA blood levels. Based on earlier data showing efficacy in prevention of prostate cancer development using 5 alpha-reductase inhibitors, a trial of dutastaride was undertaken.Chemoprevention using dutasteride: the REDUCE trial Curr Opin Urol. 2005 Jan;15(1):29-32www.ncbi.nlm.nih.gov/pubmed/15586026
-
November 29, 2009
Urologists would like the dutasteride study on prostate cancer to go on.
-
Potential Drug for Prostate Cancer
November 28, 2009
Glaxo Smith Kline has withdrawn their supplemental New Drug Application for Avodart (dutasteride) in order to update their application. This drug has great promise for this disease
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.